Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: November-01-10
Credit Expiration Date: November-01-11

Faculty

Mardi Gomberg-Maitland, MD, MSc (Chair/Moderator)
Associate Professor of Medicine
Director, Pulmonary Hypertension Center
University of Chicago Medical Center
Chicago, IL

Barbara A. Cockrill, MD
Assistant Professor of Medicine
Pulmonary and Critical Care Medicine
Brigham and Women's Hospital
Boston, MA

Ivan M. Robbins, MD
Associate Professor of Medicine
Director, Adult Pulmonary Hypertension Center
Director, Flolan Program
Vanderbilt University Medical Center
Division of Allergy, Pulmonary & Critical Care Medicine
Nashville, TN

Credit Hours

1 hour

Medium

Online Presentation

Program Description

Pulmonary Arterial Hypertension (PAH) comprises a group of diseases characterized by vascular proliferation and a progressive increase in pulmonary vascular resistance that ultimately leads to right ventricular failure and early mortality. Three classes of drugs (prostanoids, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors) have been approved for the treatment of PAH. Still more clinical trials are being conducted to examine promising new therapies, and PAH guidelines are being revised for existing therapies. Clinicians are struggling to integrate this wave of new therapies and research into effective evidence-based guidelines. Since PAH is such a heterogeneous and relatively uncommon disorder, patients’ unique clinical histories and their specific form of PAH must be taken into account when selecting a treatment strategy.

Clinicians may have difficulty evaluating patients with PAH because they are not aware of the latest advances in diagnosis and patient monitoring. Once a diagnosis is made, clinicians ought to be tailoring treatments based on the patient’s PAH classification. Many clinicians do not have a strong understanding of the mechanisms of action and possible adverse events of the available treatments. To address these gaps, this continuing education program aims to increase physicians' awareness of the indicators of PAH, how to evaluate and diagnose PAH, choices of therapy to optimize patient outcomes, and current best practices in patient monitoring.

Program Developer/Facilitator

Jointly Provided by the University of California, Irvine School of Medicine and
MCM Education

Target Audience

Designed for pulmonologists, cardiologists, and critical care specialists interested in the treatment of patients with pulmonary arterial hypertension.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Recognize the recent changes in the classifications of PAH.
  2. Outline the appropriate diagnostic steps to assess patients for PAH.
  3. Apply relevant data from clinical trials to treatment of patients for PAH.
  4. Describe how to individualize PAH treatments based on patient factors and comorbidities.

Disclosures

It is the policy of the University of California, Irvine School of Medicine and the University of California CME Consortium to ensure balance, independence, objectivity and scientific rigor in all CME activities. Full disclosure of conflict resolution can be found below.

Dr. Gomberg-Maitland discloses that she is a consultant and on a steering committee for Gilead, Medtronic, and Pfizer; receives research funding from Actelion, Gilead, Pfizer, and United Therapeutics; and has received honorarium from United Therapeutics, which could be perceived as a potential conflict of interest in this presentation. Dr. Gomberg-Maitland has disclosed that based on her potential conflict of interest her presentation has been peer reviewed for evidence base and fair balance.

Dr. Robbins discloses that he has received grant/research funding from Actelion, BioMarin, Novartis, and is a member of advisory/review panel and honorarium recipient from Actelion, Bayer, Gilead, and United Therapeutics, which could be perceived as a potential conflict of interest in this presentation. Dr. Robbins has disclosed that based on his potential conflict of interest his presentation has been peer reviewed for evidence base and fair balance.

Dr. Cockrill has no related financial conflicts to disclose.

In accordance with the ACCME Essential Areas and policies regarding commercial support, the audience is advised that the following faculty will discuss unlabeled or unapproved uses of drugs or devices.

Dr. Gomberg-Maitland’s, Dr. Robbins’, and Dr. Cockrill's presentations will include discussion of off-label, experimental, and/or investigational uses of bosentan and sildenafil in the management and treatment of patients with pulmonary arterial hypertension.

Conflict Resolution: All presentations have been peer reviewed for evidence base and fair balance.

The CME Office Staff of the University of California, Irvine School of Medicine and Medical Communications Media, Inc. have nothing to disclose. The Peer Reviewer, Dr. Samuel Wilson, MD, has disclosed he has no relationships with any commercial entity. The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, Irvine School of Medicine or Medical Communications Media, Inc.

Credit Statements

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of California, Irvine School of Medicine and Medical Communications Media, Inc. The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The University of California, Irvine School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

California Assembly Bill 1195
This activity is in compliance with California Assembly Bill 1195, which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. For specific information regarding Bill 1195 and definitions of cultural and linguistic competency, please visit the CME website: http://www.meded.uci.edu/CME/CME-H-AB1195.htm.

This activity should take approximately 60 minutes to complete. There is no fee to participate and receive credit. Credit is awarded for scores of 70% or better on the post-test. Statements of credit can be printed immediately for online submissions or will be mailed to participants within 6 weeks for mailed/faxed submissions.

Commercial Support Statements

.

Certificate Fee

$0.00

Disclaimer

MCM LOGO © 2010, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher; the University of California, Irvine; Actelion Pharmaceuticals; or Gilead. Any medications, diagnostic procedures, or treatments discussed by the program faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS